KROESE, Tiuri E, Sebastiaan BRONZWAER, Peter S N VAN ROSSUM, Sebastian F SCHOPPMAN, Pieter R A J DESEYNE, Eric VAN CUTSEM, Karin HAUSTERMANS, Philippe NAFTEUX, Melissa THOMAS, Radka LORDICK OBERMANNOVÁ, Hanna R MORTENSEN, Marianne NORDSMARK, Per PFEIFFER, Anneli ELME, Antoine ADENIS, Guillaume PIESSEN, Christiane J BRUNS, Florian LORDICK, Ines GOCKEL, Markus MOEHLER, Cihan GANI, Theodore LIAKAKOS, John V REYNOLDS, Alessio G MORGANTI, Riccardo ROSATI, Carlo CASTORO, Francesco CELLINI, Domenico D'UGO, Franco ROVIELLO, Maria BENCIVENGA, de Manzoni GIOVANNI, Mark I van Berge HENEGOUWEN, Maarten C C M HULSHOFF, Jolanda VAN DIEREN, Marieke VOLLEBERGH, Johanna W VAN SANDICK, Paul JEENE, Christel MUIJS, Marije SLINGERLAND, Francine E M VONCKEN, Henk HARTGRINK, Geert-Jan CREEMERS, Maurice J C VAN DER SANGEN, Grard A P NIEUWENHUIJZEN, Maaike BERBEE, Marcel VERHEIJ, Bas WIJNHOVEN, V Beerepoot LAURENS, Nadia Haj MOHAMMAD, Stella MOOK, Jelle P RUURDA, Piotr KOLODZIEJCZYK, Wojciech P POLKOWSKI, Lucjan WYRWICZ, Maria ALSINA, Josep TABERNERO, Manuel PERA, Tania F KANONNIKOFF, Andres CERVANTES, Magnus NILSSON, Stefan MONIG, Anna D WAGNER, Matthias GUCKENBERGER, Ewen A GRIFFITHS, Elizabeth SMYTH, George B HANNA, Sheraz MARKAR, M Asif CHAUDRY, Maria A HAWKINS, Edward CHEONG, Hanneke W M VAN LAARHOVEN a Richard VAN HILLEGERSBERG. European clinical practice guidelines for the definition, diagnosis, and treatment of oligometastatic esophagogastric cancer (OMEC-4). European Journal of Cancer. London: ELSEVIER, 2024, roč. 204, June 2024, s. 1-9. ISSN 0959-8049. Dostupné z: https://dx.doi.org/10.1016/j.ejca.2024.114062.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název European clinical practice guidelines for the definition, diagnosis, and treatment of oligometastatic esophagogastric cancer (OMEC-4)
Autoři KROESE, Tiuri E, Sebastiaan BRONZWAER, Peter S N VAN ROSSUM, Sebastian F SCHOPPMAN, Pieter R A J DESEYNE, Eric VAN CUTSEM, Karin HAUSTERMANS, Philippe NAFTEUX, Melissa THOMAS, Radka LORDICK OBERMANNOVÁ (203 Česká republika, domácí), Hanna R MORTENSEN, Marianne NORDSMARK, Per PFEIFFER, Anneli ELME, Antoine ADENIS, Guillaume PIESSEN, Christiane J BRUNS, Florian LORDICK, Ines GOCKEL, Markus MOEHLER, Cihan GANI, Theodore LIAKAKOS, John V REYNOLDS, Alessio G MORGANTI, Riccardo ROSATI, Carlo CASTORO, Francesco CELLINI, Domenico D'UGO, Franco ROVIELLO, Maria BENCIVENGA, de Manzoni GIOVANNI, Mark I van Berge HENEGOUWEN, Maarten C C M HULSHOFF, Jolanda VAN DIEREN, Marieke VOLLEBERGH, Johanna W VAN SANDICK, Paul JEENE, Christel MUIJS, Marije SLINGERLAND, Francine E M VONCKEN, Henk HARTGRINK, Geert-Jan CREEMERS, Maurice J C VAN DER SANGEN, Grard A P NIEUWENHUIJZEN, Maaike BERBEE, Marcel VERHEIJ, Bas WIJNHOVEN, V Beerepoot LAURENS, Nadia Haj MOHAMMAD, Stella MOOK, Jelle P RUURDA, Piotr KOLODZIEJCZYK, Wojciech P POLKOWSKI, Lucjan WYRWICZ, Maria ALSINA, Josep TABERNERO, Manuel PERA, Tania F KANONNIKOFF, Andres CERVANTES, Magnus NILSSON, Stefan MONIG, Anna D WAGNER, Matthias GUCKENBERGER, Ewen A GRIFFITHS, Elizabeth SMYTH, George B HANNA, Sheraz MARKAR, M Asif CHAUDRY, Maria A HAWKINS, Edward CHEONG, Hanneke W M VAN LAARHOVEN a Richard VAN HILLEGERSBERG.
Vydání European Journal of Cancer, London, ELSEVIER, 2024, 0959-8049.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30204 Oncology
Stát vydavatele Velká Británie a Severní Irsko
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 8.400 v roce 2022
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.1016/j.ejca.2024.114062
UT WoS 001284009600001
Klíčová slova anglicky Esophageal cancer; Gastric cancer; Metastasis; Metastasectomy; Stereotactic body radiotherapy; Oligometastasis
Štítky 14110811, rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Tereza Miškechová, učo 341652. Změněno: 15. 8. 2024 12:02.
Anotace
Introduction: The OligoMetastatic Esophagogastric Cancer (OMEC) project aims to provide clinical practice guidelines for the definition, diagnosis, and treatment of esophagogastric oligometastatic disease (OMD). Methods: Guidelines were developed according to AGREE II and GRADE principles. Guidelines were based on a systematic review (OMEC-1), clinical case discussions (OMEC-2), and a Delphi consensus study (OMEC-3) by 49 European expert centers for esophagogastric cancer. OMEC identified patients for whom the term OMD is considered or could be considered. Disease-free interval (DFI) was defined as the time between primary tumor treatment and detection of OMD. Results: Moderate to high quality of evidence was found (i.e. 1 randomized and 4 non-randomized phase II trials) resulting in moderate recommendations. OMD is considered in esophagogastric cancer patients with 1 organ with <= 3 metastases or 1 involved extra-regional lymph node station. In addition, OMD continues to be considered in patients with OMD without progression in number of metastases after systemic therapy. F-18-FDG PET/CT imaging is recommended for baseline staging and for restaging after systemic therapy when local treatment is considered. For patients with synchronous OMD or metachronous OMD and a DFI <= 2 years, recommended treatment consists of systemic therapy followed by restaging to assess suitability for local treatment. For patients with metachronous OMD and DFI > 2 years, upfront local treatment is additionally recommended. Discussion: These multidisciplinary European clinical practice guidelines for the uniform definition, diagnosis and treatment of esophagogastric OMD can be used to standardize inclusion criteria in future clinical trials and to reduce variation in treatment.
VytisknoutZobrazeno: 22. 8. 2024 01:34